Stock futures are inching lower, reflecting a shift toward more defensive posturing ahead of key inflation data and further signals from the Fed. Equity markets look set to open with a cautious tone again today following two down days for stocks.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Gold is maintaining its firm footing, buoyed by a slightly weaker U.S. dollar and the growing consensus that the Fed may tolerate elevated inflation in order to support employment. Spot gold is hovering just under its recent peaks.
Adding to investor unease is the looming threat of a U.S. government shutdown, with budget talks stalling. A shutdown could delay economic data, impair regulatory oversight, and complicate capital markets operations.
In pre-market trading, S&P 500 futures fell 0.42%, Nasdaq futures fell 0.62% and Dow futures fell 0.21%.
Check out this morning’s top movers from around Wall Street, compiled by The Fly, and subscribe to the Fly By on YouTube.
HIGHER –
- Vertex Pharmaceuticals (VRTX) up 1% after announcing advancements across its kidney portfolio and being upgraded at Leerink
- Citi (C) up 1% after disclosing that CHPAF Holdings has agreed to purchase from Citi an equity stake in Grupo Financiero Banamex for $2.3B
UP AFTER EARNINGS –
DOWN AFTER EARNINGS –
- CarMax (KMX) down 15%
- Jabil (JBL) down 6%
- TD Synnex (SNX) down 4%
- Stitch Fix (SFIX) down 9%
- KB Home (KBH) down 1%
LOWER –
- DarioHealth (DRIO) down 11% after announcing that its board of directors has initiated a strategic review following multiple unsolicited inbound strategic inquiries from interested parties
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals granted breakthrough therapy designation for povetacicept
- Vertex Pharmaceuticals completes enrollment in IA cohort of AMPLITUDE trial
- Vertex Pharmaceuticals initiates AGLOW study of VX-407
- Leerink ups Vertex Pharmaceuticals to Outperform on stock pullback, solid growth
- Vertex Pharmaceuticals upgraded to Outperform from Market Perform at Leerink